Crossmark

Performance of a DNA methylation marker panel using liquid-based cervical scrapes to detect cervical cancer and its precancerous stages

Crossref DOI link: https://doi.org/10.1186/s12885-018-5125-8

Published Online: 2018-12-03

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Schmitz, Martina http://orcid.org/0000-0003-2430-3500
Eichelkraut, Kristin

Schmidt, Dana

Zeiser, Ilona

Hilal, Ziad

Tettenborn, Zena

Hansel, Alfred

Ikenberg, Hans
License Information

Text and Data Mining valid from 2018-12-01
More Information

Article History

Received: 2 July 2018

Accepted: 22 November 2018

First Online: 3 December 2018

Ethics approval and consent to participate

: This study was designed as a quality development study, utilizing only residual material that otherwise would have been discarded. All patient samples were surplus samples and completely anonymized prior to use in the study. The study was performed following the guideline of the Declaration of Helsinki. According to German law an ethical approval is not required if using completely anonymized surplus samples in such a retrospective study setting.

: Not applicable.

: MS, AH, KE and DS are shareholders and/or employees of oncgnostics GmbH, a company that aims to commercialize DNA methylation markers.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.